By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Panacos Pharmaceuticals Inc. 

134 Coolidge Avenue

Watertown  Massachusetts  02472  U.S.A.
Phone: 617-926-1551 Fax: 617-923-2276


Panacos Pharmaceuticals Inc. is developing the next generation of anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. HIV infects approximately 1.7 million people in North America and Western Europe and approximately 40 million people worldwide. Approximately 650,000 patients are treated annually for HIV in the United States and Western Europe. Resistance to currently available drugs is one of the most pressing problems in HIV therapy and the leading cause of treatment failure. Panacos' proprietary discovery technologies are designed to combat resistance by focusing on novel targets in the virus life cycle, including virus maturation and virus fusion.

Panacos' lead candidate, bevirimat (PA-457), is the first in a new class of oral HIV therapeutics under development called maturation inhibitors, discovered by Panacos scientists and their academic collaborators. Based on its novel mechanism of action, bevirimat is designed to have potent activity against a broad range of HIV, including strains that are resistant to existing classes of drugs. The Company has completed seven clinical studies of bevirimat in over 300 subjects, showing significant reductions in viral load in HIV-infected subjects and a promising safety profile, and is currently in Phase 2b clinical trials.

The US Food and Drug Administration (FDA) has granted Fast Track designation to bevirimat. Fast Track is a process designed to expedite development and approval of new drugs that may have the potential to improve treatment for serious or life-threatening diseases. Developers of Fast Tracked products have greater access to FDA resources as well as eligibility for rolling NDA submissions. In addition, Fast Track designation may enable priority FDA review and accelerated approval.

In addition to bevirimat, Panacos is developing second generation maturation inhibitors and small molecule inhibitors of HIV fusion.

Last Updated: 11-17-2006

Key Statistics

Ownership: Public

Web Site: Panacos Pharmaceuticals Inc.
Employees: 40
Symbol: PANC



University of North Carolina  Chapel Hill - Professor K.H. Lee is a leading natural products chemist with whom Panacos collaborates to screen natural products, and identify and optimize novel antiviral drugs.

NCI  Panacos has a CRADA with leading scientists at the National Cancer Institute to study the mechanism of HIV maturation inhibitors and to discover new antiviral drugs.

Evotec Technologies GmbH  Medicinal chemistry collaboration for novel drug candidates.

Company News
Panacos Pharmaceuticals Inc. (PANC) Provides Corporate and Strategic Update 2/24/2009 10:22:19 AM
Panacos Pharmaceuticals Inc. (PANC) Shutters Gaithersburg Office; Will Shrink to Four Employees 2/24/2009 8:30:26 AM
Panacos Pharmaceuticals Inc. (PANC) Announces Additional Personnel Departures 2/12/2009 11:03:13 AM
Panacos Pharmaceuticals Inc. (PANC) Announces Repayment of Hercules Loan 11/24/2008 9:59:42 AM
Panacos Pharmaceuticals Inc. (PANC) Announces Preliminary Results of Bevirimat Study 204 10/28/2008 10:41:14 AM
Panacos Pharmaceuticals Inc. (PANC) Presents Phase 2b Bevirimat Data at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 10/27/2008 11:07:35 AM
Panacos Pharmaceuticals Inc. (PANC)’ Study 114 Supports The Company’s New Tablet Formulation Of Bevirimat 10/8/2008 11:02:03 AM
Panacos Pharmaceuticals Inc. (PANC) Reports Second Quarter 2008 Financial Results 7/31/2008 10:58:53 AM
Panacos Pharmaceuticals Inc. (PANC) to Present at Oppenheimer Small and Mid Cap Clinical and Regulatory Conference 7/31/2008 9:15:19 AM
Panacos Pharmaceuticals Inc. (PANC) Announces Stock Listing Transfer to The Nasdaq Capital Market 7/30/2008 9:14:26 AM